– USA, CT – Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical, today announced the additions of Barbara Ryan and John Schroer to its Board of Directors.
“We are thrilled to further strengthen the Azitra team by welcoming Barbara and John to our board and by leveraging their wealth of knowledge in biotech, corporate strategy, and capital markets. Both Barbara and John are widely recognized leaders in biotech, and their additions to Azitra’s board will be invaluable as we grow the company to support clinical trials and our partnership with Bayer,” said CEO, Francisco Salva.
About Barbara Ryan
Barbara Ryan is a Board Member of Indivior PLC and MiNK Therapeutics, the CEO of Barbara Ryan Advisors, and a Senior Advisor at Ernst & Young. Previously, Ms. Ryan was a Wall Street research analyst, Managing Director, and Head of Pharmaceutical Research at Deutsche Bank. She began her career covering the pharmaceutical industry at Bear Stearns. She has been the lead analyst on high-profile transactions and has raised over $1.5 billion for emerging biopharma companies in IPOs, follow-ons, PIPEs, and convertible debt transactions. She has led the IR/PR programs, or served as senior strategic investor relations counsel, to firms including Shire, Cardinal Health, Zoetis, Allergan, Perrigo Agenus, Radius Health, Rafael Holdings, Centrexion, Esperion, ContraFect, Relypsa, Syndax, Barbara is a member of the Editorial Advisory Board of Pharmaceutical Executive magazine where she authors a monthly finance column and is a faculty member at the GLG Institute.
About John Schroer
John Schroer is CFO at Alumis, where he started in March 2022. Previously, he was CFO at ArsenalBio from February 2021 to February 2022. Before that role, Mr. Schroer served as CFO and treasurer at Translate Bio. From January 2014 to April 2018, Mr. Schroer served as a director and sector head – of healthcare at Allianz Global Investors, a global asset management company. From 2009 to December 2013, he served as president and CIO at Schroer Capital, LP, a financial services company that he founded.
“Azitra is an innovative company that is bringing much-needed novel therapies to patients suffering from severe skin diseases, which often have few or no therapeutic options,” said John Schroer. “I am delighted to join Azitra’s board and look forward to working closely with the team on strategies to successfully grow the company and deliver value to both patients and shareholders.”
Mr. Schroer received a B.S. in history and international relations and an MBA from the University of Wisconsin-Madison.
About Azitra, Inc.
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company’s library of strains for drug-like molecules. The Company’s initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering dermatologic therapies.
Source: https://azitrainc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.